Fibroscan / VCTE: Drugs That Distort This Test

What Fibroscan / VCTE Actually Measures

Fibroscan sends a low-frequency shear wave through liver tissue and measures how fast it travels. Stiffer tissue propagates the wave faster, producing a higher kPa reading. The device simultaneously captures a Controlled Attenuation Parameter (CAP) score, which estimates hepatic fat by analyzing ultrasound signal attenuation. A detailed technical overview is available from the FDA's 510(k) database for the Fibroscan 502 Touch.

Why Stiffness Does Not Always Equal Fibrosis

Liver stiffness is a physical property. Fibrosis is one cause of increased stiffness, but it is not the only one. Inflammation, congestion, cholestasis, and even post-prandial blood flow can all stiffen the liver temporarily without laying down a single strand of collagen. A 2012 Journal of Hepatology meta-analysis covering 13 studies and 3,951 patients confirmed that acute hepatitis flares and bile-duct obstruction significantly inflate VCTE readings independent of fibrosis stage.

This distinction matters clinically. A patient on amiodarone with a Fibroscan of 14.2 kPa may carry a chart label of "advanced fibrosis" when the drug itself is the driver.

Validated Cutoffs by Liver Disease Etiology

Cutoffs vary by the underlying liver disease. For metabolic dysfunction-associated steatotic liver disease (MASLD), the American Association for the Study of Liver Diseases (AASLD) 2023 guidance places the F2 threshold at approximately 8.0 kPa and advanced fibrosis (F3) at 12.0 kPa. The AASLD practice guidance on MASLD, published in Hepatology, provides the full cutoff table. For chronic hepatitis C, the cirrhosis cutoff drops to around 12.5 kPa because inflammation is less likely to confound results after sustained virologic response.

Drugs That Falsely Raise Fibroscan / VCTE Scores

Several drug classes cause hepatic inflammation, steatosis, cholestasis, or vascular congestion. Each mechanism inflates liver stiffness independently of true fibrosis. A landmark EASL-ALEH 2017 clinical practice guideline on non-invasive liver tests lists these confounders explicitly.

Amiodarone and Other Antiarrhythmics

Amiodarone is among the most hepatotoxic drugs in routine cardiology use. It causes phospholipidosis, a lysosomal storage defect that produces a histologic picture resembling alcoholic hepatitis, and it can raise liver stiffness by 3-5 kPa in patients without underlying fibrosis. A 2009 case series in the American Journal of Cardiology documented liver stiffness values above 12.0 kPa in amiodarone-treated patients with normal liver biopsies. Dronedarone carries a similar, though less frequent, pattern of hepatocellular injury. If a patient cannot safely stop amiodarone before a staging Fibroscan, the clinician should note the drug on the report and apply disease-specific inflation correction.

Methotrexate

Methotrexate causes direct hepatic fibrosis with cumulative dosing, but it also causes acute inflammation at any dose that transiently stiffens the liver. The ACR recommends Fibroscan-based fibrosis monitoring for patients receiving long-term methotrexate, but the scan should be performed during a period of stable, non-inflamed liver function. A 2019 Hepatology study (N=63 rheumatology patients) found that active aminotransferase elevation on the day of VCTE correlated with a 2.1 kPa overestimate of stiffness. The practical rule: if ALT is more than twice the upper limit of normal, reschedule the scan.

Corticosteroids and Anabolic Steroids

Systemic corticosteroids accelerate hepatic steatosis and may cause steroid hepatitis, both of which inflate CAP scores and kPa readings. Anabolic-androgenic steroids (AAS) produce cholestatic hepatitis and peliosis hepatis, each of which markedly stiffens the liver. A 2018 Journal of Hepatology report identified VCTE readings above 16 kPa in bodybuilders using AAS, with values normalizing within 6 months of cessation. For patients on physiologic testosterone replacement therapy at doses that keep serum testosterone within the normal male range (400-700 ng/dL), the hepatic stiffness impact appears minimal, but data are sparse.

Statins

The relationship between statins and Fibroscan is counterintuitive. Statins generally reduce hepatic inflammation in MASLD, which should lower readings, but a subset of patients develop statin-induced hepatocellular injury that transiently raises ALT and stiffness. If a patient presents with symptomatic statin myopathy and elevated liver enzymes, the Fibroscan should be deferred until enzymes normalize. The FDA drug safety communication on statin-associated liver injury provides the current regulatory framing.

Antiretroviral Therapy

Certain antiretrovirals, particularly older nucleoside reverse-transcriptase inhibitors (NRTIs) like stavudine and didanosine, cause mitochondrial toxicity and hepatic steatosis. Protease inhibitors contribute to lipodystrophy and insulin resistance, both of which worsen MASLD independently of HIV. In HIV/HCV coinfection, VCTE readings are substantially higher than in HCV monoinfection at matched biopsy stages, a finding documented in the ANRS CO13 HEPAVIH cohort. The primary analysis from HEPAVIH, published in the Journal of Infectious Diseases, is available on PubMed.

Tamoxifen and Aromatase Inhibitors

Tamoxifen-induced hepatic steatosis occurs in up to 40% of treated patients and can raise CAP scores by 30-50 dB/m. The liver stiffness effect is secondary to the fat accumulation and associated metabolic inflammation. Aromatase inhibitors produce less steatosis but may cause a modest rise in stiffness through off-target hormonal effects on hepatic lipid metabolism. Fibroscan monitoring in breast cancer survivors on endocrine therapy should account for this drug effect when interpreting results. A 2011 Liver International study (N=88) confirmed that tamoxifen use was independently associated with elevated liver stiffness after adjusting for BMI and alcohol.

Substances That Falsely Raise Fibroscan Scores: Non-Prescription Confounders

Alcohol

Alcohol is the single most potent acute confounder of Fibroscan. A single binge-drinking episode (four or more drinks within two hours) can raise liver stiffness by 20-30% the following morning, pushing a patient from an F1 result into an apparent F2. A 2008 study in Hepatology (N=51) showed a mean kPa increase of 3.1 points 30 minutes after alcohol consumption, with values returning to baseline only after 24 hours of abstinence. All major Fibroscan protocols now require at least 24 hours of alcohol abstinence before testing. The EASL-ALEH guideline explicitly lists alcohol as a mandatory exclusion in the pre-scan preparation checklist.

Food and Recent Meals

Post-prandial hepatic blood flow increases portal venous pressure, which stiffens the liver. A 2012 Hepatology study (N=120 healthy volunteers) found that a standard meal raised VCTE readings by a mean of 1.4 kPa, with peak effect at 15-45 minutes post-meal. The full study is indexed at PubMed. A three-hour fast before Fibroscan is the standard recommendation embedded in the Echosens operator manual and endorsed by the AASLD.

Herbal Supplements With Hepatotoxic Potential

Green tea extract, kava, pyrrolizidine alkaloids (found in some traditional herbal teas), and high-dose vitamin A all cause varying degrees of hepatocellular or cholestatic injury. These raise liver stiffness by the same inflammation-mediated mechanism as prescription hepatotoxins. Patients should be specifically asked about supplements, not just prescription drugs, before any Fibroscan appointment.

Drugs That Falsely Lower Fibroscan / VCTE Scores

GLP-1 Receptor Agonists

Semaglutide and liraglutide reduce hepatic steatosis, inflammation, and possibly early fibrosis in patients with MASLD. This means Fibroscan scores genuinely improve during GLP-1 therapy. The concern is not false negativity in the traditional sense, but rather that a scan performed after 6 months of semaglutide 2.4 mg may not reflect the baseline fibrosis burden that would have been seen before treatment. The LEAN trial (liraglutide 1.8 mg, N=52) reported histologic NASH resolution in 39% of patients vs. 9% on placebo (P<0.019), with associated reductions in liver stiffness. For diagnostic staging purposes, if a patient has been on a GLP-1 agonist for more than 12 weeks, the clinician should note this on the requisition.

Resmetirom (Rezdiffra)

Resmetirom, the first FDA-approved drug for MASH-related fibrosis, was approved in March 2024 partly on the basis of Fibroscan response data. In the MAESTRO-NASH trial (N=966), resmetirom 100 mg daily reduced liver stiffness by a mean of 2.8 kPa at 52 weeks in the F2-F3 subgroup. The NEJM publication of MAESTRO-NASH is available at NEJM.org. This reduction reflects true histologic improvement, not a drug-induced measurement artifact. The distinction matters for labeling interpretation: a post-treatment Fibroscan on resmetirom showing 9.5 kPa does not mean the patient has borderline F1-F2; it means the drug is working.

Vitamin E

High-dose vitamin E (800 IU/day) reduced NASH activity scores in the PIVENS trial (N=247, 96 weeks) and produces modest reductions in hepatic steatosis and inflammation. Because it reduces inflammation rather than fibrosis, the kPa drop is typically small (under 1 kPa), but it can shift a borderline F2 result below the 8.0 kPa threshold. PIVENS was published in the New England Journal of Medicine.

The Resmetirom Indication: Why Accurate Fibroscan Staging Matters

Resmetirom carries an FDA-approved indication for adults with MASH and moderate-to-advanced liver fibrosis (F2-F3 on the METAVIR scale). The drug is not indicated for F0-F1 or for decompensated cirrhosis (F4 with complications). The FDA approval letter for resmetirom (NDA 217785) is available on the FDA website. A drug-inflated Fibroscan of 10.5 kPa in a patient who is actually F1 could result in unnecessary prescription of a drug that costs over $47,000 per year. A drug-deflated reading of 7.8 kPa in an F3 patient on semaglutide could deny them a treatment that reduces their 10-year cirrhosis risk.

The HealthRX Fibroscan Accuracy Framework recommends that every ordering clinician answer four questions before scanning:

1. Has the patient consumed alcohol in the past 24 hours? Reschedule if yes.
2. Has the patient eaten in the past 3 hours? Delay the scan if yes.
3. Is the patient on a drug with documented hepatic stiffness effects (amiodarone, methotrexate, AAS, tamoxifen, GLP-1 agonist, resmetirom)? Document on the requisition.
4. Is the ALT more than twice the upper limit of normal? Consider rescheduling unless the elevation is chronic and stable.

Normal Fibroscan / VCTE Ranges

Liver Stiffness (kPa) by Fibrosis Stage in MASLD

The AASLD 2023 MASLD guidance and the Baveno VII consensus (2022) both converge on the following approximate cutoffs for MASLD/MASH:

| Fibrosis Stage | METAVIR | Approximate kPa Range | |---|---|---| | F0-F1 | None to mild | <8.0 kPa | | F2 | Significant | 8.0-9.9 kPa | | F3 | Advanced | 10.0-13.9 kPa | | F4 | Cirrhosis | ≥14.0 kPa |

The Baveno VII consensus report, published in the Journal of Hepatology, is available on PubMed.

These cutoffs shift in different disease etiologies. In chronic hepatitis B, the cirrhosis threshold rises to about 17.0 kPa. In primary biliary cholangitis, any stiffness value must be interpreted alongside alkaline phosphatase trajectory and ursodeoxycholic acid response.

CAP Score (dB/m) by Steatosis Grade

CAP scores use a parallel scale for hepatic fat:

| Steatosis Grade | Fat Fraction | Approximate CAP | |---|---|---| | S0 | <5% | <248 dB/m | | S1 | 5-33% | 248-267 dB/m | | S2 | 34-66% | 268-279 dB/m | | S3 | >66% | ≥280 dB/m |

A 2017 meta-analysis in the Journal of Hepatology (N=2,735 patients, 10 studies) validated these CAP cutoffs against liver biopsy.

What a "Low" Fibroscan Means

A liver stiffness measurement below 5.0 kPa is reassuring and suggests no significant fibrosis. Values below 4.0 kPa are seen in healthy livers with no hepatic disease. A very low reading does not require any action beyond standard lifestyle counseling unless the clinical picture is discordant (e.g., a patient with severe obesity and markedly elevated liver enzymes whose Fibroscan reads 3.8 kPa should be re-tested after ensuring proper fasting and operator technique).

How to Lower a Fibroscan Score: Legitimate Pathways

If a high Fibroscan score reflects true fibrosis, the only way to lower it is to reverse the underlying liver disease. There are no shortcuts. But if the high reading is confounded by drugs or lifestyle factors, correcting those confounders lowers the measured kPa back to the true value.

Weight Loss

A 10% reduction in body weight produces histologic NASH resolution in approximately 45% of patients and fibrosis improvement in 19%, based on an analysis of 261 paired biopsies published in Hepatology. That study is indexed at PubMed. The corresponding VCTE drop averages 1.5-2.5 kPa per 10% weight loss, according to the same dataset.

GLP-1 Agonist Therapy

In the STEP-1 trial (N=1,961), semaglutide 2.4 mg produced 14.9% mean weight loss at 68 weeks vs. 2.4% on placebo. STEP-1 was published in the New England Journal of Medicine. The hepatic benefit from this degree of weight loss typically produces a measurable VCTE reduction within 6-12 months of sustained use.

Alcohol Cessation

Alcohol-related liver disease is the only common etiology where fibrosis can substantially reverse with cessation alone. A 2016 Gastroenterology study showed a mean kPa reduction of 6.1 points over 12 months in patients with alcohol-related liver disease who achieved sustained abstinence. That study is available on PubMed.

How to Get an Accurate Fibroscan Result: Pre-Scan Checklist

Getting the number right the first time matters. Each repeat scan costs time, money, and sometimes a treatment delay.

• Fast for 3 hours. Two hours is the published minimum; three hours is safer.
• No alcohol for 24 hours. The EASL-ALEH guideline specifies this explicitly.
• Disclose all drugs and supplements to the ordering clinician before the scan, not after.
• Check liver enzymes first. If ALT is more than twice the upper limit of normal and the elevation is acute rather than chronic, reschedule.
• BMI above 40 kg/m² reduces success rate. The XL probe increases success rate in obese patients; confirm the testing center has it available.
• Right lateral decubitus position is required. Upright or supine scanning produces artifactually different readings.

The Echosens user manual and Fibroscan technical specifications are summarized in the original FDA 510(k) clearance documentation.